Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Sarepta Therapeutics Inc (SRPT): Today's Featured Drugs Laggard

Tickers in this article: SRPT

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model

Sarepta Therapeutics (SRPT) pushed the Drugs industry lower today making it today's featured Drugs laggard. The industry as a whole closed the day up 2.0%. By the end of trading, Sarepta Therapeutics fell $0.89 (-2.6%) to $32.86 on average volume. Throughout the day, 1,717,841 shares of Sarepta Therapeutics exchanged hands as compared to its average daily volume of 1,808,600 shares. The stock ranged in price between $32.78-$34.72 after having opened the day at $33.80 as compared to the previous trading day's close of $33.75. Other companies within the Drugs industry that declined today were: Aoxing Pharmaceutical Company (AXN), down 17.6%, Atossa Genetics (ATOS), down 10.1%, Zalicus (ZLCS), down 5.6% and Celsion Corporation (CLSN), down 5.4%.

  • EXCLUSIVE OFFER: Jim Cramer's Protege, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

Sarepta Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery and development of RNA-based therapeutics for the treatment of rare and infectious diseases. Sarepta Therapeutics has a market cap of $1.1 billion and is part of the health care sector. Shares are up 36.2% year to date as of the close of trading on Thursday.

TheStreet Ratings rates Sarepta Therapeutics as a sell. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, disappointing return on equity and feeble growth in its earnings per share.

On the positive front, Vertex Pharmaceuticals (VRTX), down 61.9%, Catalyst Pharmaceutical Partners (CPRX), down 56.7%, Anacor Pharmaceuticals (ANAC), down 13.6% and Ligand Pharmaceuticals (LGND), down 10.3% , were all gainers within the drugs industry with Johnson & Johnson (JNJ) being today's featured drugs industry leader.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF (XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech (BIS).

Exclusive Offer: Jim Cramer's 'go-to' small/mid-cap guru Bryan Ashenberg only buys stocks he thinks could return 50-100%. See his top picks for 14-days FREE.